China’s Biotech Companies Just Captured Half of Global Pharma Licensing Deals, Hit $60 Billion in Q1, and Their Executives Say the Global Push Is Now Irreversib... (opens in new tab)

Chinese biotech firms struck a record $60 billion in cross-border licensing deals during the first quarter of 2026, a 73 percent jump from the same quarter a year earlier, with Chinese-originated drug candidates now accounting for approximately 50 percent of global biotech business-development deal flow, Innovent's mazdutide obesity drug delivering Phase 3 trial data that suggests greater weight-loss efficacy than Novo Nordisk's semaglutide, and industry executives explicitly characterising t...